

Chorionic gonadotropin, Pregnyl, Novarel, Ovidrel

CareFirst Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-855-330-1720**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-888-877-0518**. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do_not_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name:		Date:
Patient's ID:		Patient's Date of Birth:
Physician's Name:		
Specialty:		NPI#:
Physician Office Telephone:		Physician Office Fax:
Referring Provider Info: ☐ Same as Re	questing Provi	der
Name:		NPI#:
Fax:		Phone:
Rendering Provider Info: ☐ Same as Re	eferring Provid	er 🗆 Same as Requesting Provider
Name:		NPI#:
Fax:		Phone:
	-	in accordance with FDA-approved labeling, vidence-based practice guidelines.
Patient Weight:	kg	
Patient Height:	cm	
Please indicate the place of service for the	requested drug.	•
☐ Ambulatory Surgical	\square Home	Off Campus Outpatient Hospital
☐ On Campus Outpatient Hospital	☐ Office	\square Pharmacy
What is the ICD-10 code?		

Exception Criteria Questions:				
A. What is the prescribed product?				
\square chorionic gonadotropin (generic for Pregnyl), <i>Continue to Question B</i>				
☐ Novarel (chorionic gonadotropin), <i>Continue to Question B</i>				
☐ Ovidrel (choriogonadotropin alfa), Skip to Clinical Criteria Questions				
☐ Pregnyl (chorionic gonadotropin), Skip to Clinical Criteria Questions				
B. The preferred products for your patient's health plan are Ovidrel and Pregnyl. Can the patient's treatment be switched to one of the preferred products?				
☐ Yes, Ovidrel, Skip to Clinical Criteria Questions				
☐ Yes, Pregnyl, Skip to Clinical Criteria Questions				
\square No, Continue to Question C				
C. Does the patient have a documented inadequate response, contraindication, or intolerable adverse event to either of the preferred products (Ovidrel or Pregnyl)? <i>ACTION REQUIRED: If Yes, attach supporting chart note(s)</i>				
☐ Yes, Continue to Clinical Criteria Questions				
□ No, Continue to Clinical Criteria Questions				
Criteria Questions: 1. What is the patient's diagnosis or the type of procedure the patient will be undergoing?				
☐ Ovulation induction (e.g., intrauterine insemination [IUI]), <i>No further questions</i> ☐ Assisted reproductive technology (e.g., in vitro fertilization [IVF], frozen embryo transfer [FET], gamete intrafallopian transfer [GIFT], zygote intrafallopian transfer [ZIFT], Intracytoplasmic sperm injection [ICSI]), <i>No further questions</i>				
☐ Prepubertal cryptorchidism, <i>No further questions</i>				
☐ Hypogonadotropic hypogonadism, <i>Continue to 2</i>				
☐ Other, please specify:, No further questions				
 2. Does the patient have a low pretreatment testosterone level? <i>ACTION REQUIRED</i>: If Yes, attach laboratory results of testosterone level. ☐ Yes, <i>Continue to 3</i> ☐ No, <i>Continue to 3</i> 				
3. Does the patient have low or low to normal levels of follicle stimulating hormone (FSH) or luteinizing hormone (LH)? <i>ACTION REQUIRED</i> : Attach laboratory results of FSH or LH levels. The Yes - Follicle stimulating hormone (FSH) level <i>ACTION REQUIRED</i> : Submit supporting documentation, No further questions The Yes - Luteinizing hormone (LH) level <i>ACTION REQUIRED</i> : Submit supporting documentation, No further questions				
□ No, No further questions				

Step Therapy Override: Complete if Applicable for the state of Maryland.		Please Circle	
Is the requested drug being used to treat stage four advanced metastatic cancer?	Yes	No	
Is the requested drug's use consistent with the FDA-approved indication or the National Comprehensive Cancer Network Drugs & Biologics Compendium indication for the treatment of stage four advanced metastatic cancer and is supported by peer-reviewed medical literature?		No	
Is the requested drug being used for an FDA-approved indication OR an indication supported in the compendia of current literature (examples: AHFS, Lexicomp, Clinical Pharmacology, Micromedex, current accepted guidelines)?		No	
Does the prescribed quantity fall within the manufacturer's published dosing guidelines or within dosing guidelines found in the compendia of current literature (examples: package insert, AHFS, Lexicomp, Clinical Pharmacology, Micromedex, current accepted guidelines)?		No	
Do patient chart notes document the requested drug was ordered with a paid claim at the pharmacy, the pharmacy filled the prescription and delivered to the patient or other documentation that the requested drug was prescribed for the patient in the last 180 days?		No	
Has the prescriber provided proof documented in the patient chart notes that in their opinion the requested drug is effective for the patient's condition?		No	

Step Therapy Override: Complete if Applicable for the state of Virginia.		Please Circle	
Is the requested drug being used for an FDA-approved indication or an indication supported in the compendia of current literature (examples: AHFS, Micromedex, current accepted guidelines)?	Yes	No	
Does the prescribed dose and quantity fall within the FDA-approved labeling or within dosing guidelines found in the compendia of current literature?		No	
Is the request for a brand drug that has an AB-rated generic equivalent or interchangeable biological product available?		No	
Has the patient had a trial and failure of the AB-rated generic equivalent or interchangeable biological product due to an adverse event (examples: rash, nausea, vomiting, anaphylaxis) that is thought to be due to an inactive ingredient?		No	
Is the preferred drug contraindicated?		No	
Is the preferred drug expected to be ineffective based on the known clinical characteristics of the patient and the prescription drug regimen?		No	
Has the patient tried the preferred drug while on their current or previous health benefit plan and it was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event?		No	
Is the patient currently receiving a positive therapeutic outcome with the requested drug for their medical condition?	Yes	No	

I attest that this information is accurate and true, and that documentation supporting this	
information is available for review if requested by CVS Caremark or the benefit plan sponso	r.

X	
Prescriber or Authorized Signature	Date (mm/dd/yy)